United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 163,782 shares of the biotechnology company's stock after selling 2,020 shares during the quarter. Schroder Investment Management Group owned about 0.37% of United Therapeutics worth $58,575,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC increased its stake in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after acquiring an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after purchasing an additional 32,213 shares during the period. Geode Capital Management LLC increased its position in United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after purchasing an additional 45,566 shares during the last quarter. Pacer Advisors Inc. increased its position in United Therapeutics by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock worth $210,869,000 after purchasing an additional 30,931 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock worth $164,978,000 after purchasing an additional 50,409 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $388.25.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $939,625.74. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,500 shares of company stock worth $26,134,500 over the last 90 days. 11.90% of the stock is owned by insiders.

United Therapeutics Trading Down 1.6 %

UTHR traded down $4.90 during trading hours on Thursday, hitting $307.36. 431,930 shares of the company's stock were exchanged, compared to its average volume of 450,164. The firm has a 50 day moving average of $336.64 and a 200 day moving average of $355.09. The firm has a market cap of $13.80 billion, a P/E ratio of 13.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $227.75 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. As a group, research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.